{
    "2018-05-24": [
        [
            {
                "time": "2018-03-29",
                "original_text": "AbbVie Is The Amazon Of Biopharma — But Can It Keep Going?",
                "features": {
                    "keywords": [
                        "Amazon",
                        "Biopharma",
                        "growth"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "biopharma"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-04-10",
                "original_text": "IMBRUVICA® (ibrutinib) Plus GAZYVA® (obinutuzumab) Phase 3 iLLUMINATE Trial for First-Line Therapy of Chronic Lymphocytic Leukemia (CLL) Patients Met Primary Endpoint",
                "features": {
                    "keywords": [
                        "IMBRUVICA",
                        "GAZYVA",
                        "Phase 3",
                        "trial success",
                        "CLL"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-05-15",
                "original_text": "Is the Options Market Predicting a Spike in AbbVie (ABBV) Stock?",
                "features": {
                    "keywords": [
                        "options market",
                        "spike",
                        "prediction"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "finance"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-06-20",
                "original_text": "Wired News – CytomX Gets FDA Approval for Investigational New Drug Application, Triggers $25 Million Milestone Payment from AbbVie",
                "features": {
                    "keywords": [
                        "CytomX",
                        "FDA approval",
                        "milestone payment",
                        "partnership"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "biotechnology"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-07-12",
                "original_text": "AbbVie Says Phase 3 ILLUMINATE Trial Met Primary Endpoint Of Improvement In PFS",
                "features": {
                    "keywords": [
                        "Phase 3",
                        "ILLUMINATE",
                        "PFS improvement",
                        "trial success"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            }
        ]
    ]
}